Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series B raises $7.5mm for Ocugen

Executive Summary

Ocugen Inc. (therapies for eye diseases) raised $7.5mm in its Series B financing led by Turkish pharmaco Abdi Ibrahim and JSC Lancaster Group, which were joined by two returning individual investors. The company will use the money to move its OCU100 for retinitis pigmentosa and OCU200 for wet age-related macular degeneration into the clinic.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies